Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Viking Therapeutics, Inc.NASDAQ: VKTX
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $115.75M rose 92.4% year over year, behind the +227.9% change in trailing-twelve-month research & development. Sequentially, it fell 22.9% from the prior quarter. Over 3 fiscal years it compounded at +85.3% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +92.4% toward the trailing-twelve-month pace of +227.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 344.96M USD
- Year-over-year change
- +239.4%
- 4-year CAGR
- +66.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 344.96M | +239.4% |
| FY2024 | 2024-12-31 | 101.64M | +59.3% |
| FY2023 | 2023-12-31 | 63.81M | +17.6% |
| FY2022 | 2022-12-31 | 54.23M | +20.6% |
| FY2021 | 2021-12-31 | 44.98M | — |
Research & Development vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 research & development of $509.32M is the highest of the 7 companies compared; the peer median is $120.89M.
- Its year-over-year change of +227.9% is the highest of 6, against a peer median of +56.0%.
- Over three fiscal years its annual growth of +85.3% compares with a peer median of +17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $509.32M | +227.9% | +85.3% | — | |
| LTM Jun 2026 | $490.14M | +154.4% | +16.5% | 38.2% | |
| LTM Jun 2026 | $148.75M | +4.1% | +17.8% | 2088.9% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M | +56.0% | — | 137.8% |
KLRAKailera Therapeutics, Inc. | FY2025 | $109.11M | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M | +35.7% | +54.7% | — |
| LTM Mar 2026 | $24.01M | +104.7% | +13.1% | 65.2% | |
| Peer median (excluding VKTX) | $120.89M | +56.0% | +17.2% | 101.5% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 431K |
| Gross Profit | 0 | 0 | 0 | 0 | (431K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.98M | 54.23M | 63.81M | 101.64M | 344.96M |
| Selling, General & Admin | 10.7M | 16.12M | 37.02M | 49.28M | 48.39M |
| Operating Expenses | 55.68M | 70.36M | 100.83M | 150.92M | 393.34M |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| EBITDA | (54.68M) | (68.52M) | (85.52M) | (109.52M) | (359.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (55.68M) | (70.36M) | (100.83M) | (150.92M) | (393.34M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 703K | 1.59M | 15.02M | 40.94M | 33.7M |
| Interest Expense | 18K | 59K | 88K | 94K | 0 |
| Other Income / Expenses | 692K | 1.49M | 14.93M | 40.96M | 33.7M |
| Income Before Tax | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| EPS (Diluted) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| Weighted Avg Shares | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
| Weighted Avg Shares (Diluted) | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.